SENIOR LEADERSHIP
高层领导
基本信息
- 批准号:8709459
- 负责人:
- 金额:$ 7.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-01 至 2014-07-31
- 项目状态:已结题
- 来源:
- 关键词:Basic ScienceBudgetsCancer CenterCancer ControlClinical ResearchClinical SciencesEducationEnsureEnvironmentEquilibriumFinancial SupportFutureGrowthHealth PromotionHispanicsIndividualInstitutesLeadershipNCI Center for Cancer ResearchPositioning AttributeRecruitment ActivityResearchResource SharingResourcesRoleSite VisitSouth TexasTimeTranslatingTranslational ResearchUnited States National Institutes of Healthauthoritycancer carecancer preventioncancer therapyexpectationmeetingsmemberoutreachpractical applicationprogramspublic trustskillssuccess
项目摘要
Senior Leadership are individuals with the requisite skill sets that in their totality, provide a balanced and
complete perspective on our Cancer Center to ensure its optimal growth, function, resource utilization, and
intra- and inter-programmatic interactions. These individuals also represent relevant aspects of Cancer
Center affairs to the various clinical and research entities that comprise our matrix environment to ensure
that the Cancer Center interacts to best advantage and can best capitalize on available external resources.
Leadership includes the Cancer Center Executive Director (Dr. Curiel) and Deputy Director (Dr. Giles), our
three scientific Associate Directors, Dr. Slaga (Basic and Translational Research), Dr. Naylor (Shared
Resources and Internal Education) and Dr. Pollock (Cancer Prevention and Control). Dr. Ramirez serves as
Senior Leadership owing to her directorship of the Institute for Health Promotion Research, which serves a
critical cancer prevention and Hispanic outreach function for our Cancer Center. We also have an interim
Associate Director of Administration with greatly augmented authority and a clear Senior Leadership role as
requested in the prior review. A national search for a permanent Associate Director of Administration is
undenway, with the expectation that the permanent position will be filled by the time of the site visit. The
Senior Leadership ensures that our Cancer Center discharges its public trust through appropriate
stewardship of NCI, NIH and related, institutional and philanthropic dollars to translate discoveries into
practical applications that provide for the clinical and research cancer care needs of San Antonio, South
Texas and the nation. All Senior Leadership members sit on the Executive Committee and other important
committees that set current Cancer Center agendas, plan for future growth, challenges and opportunities
and help set budgets, recruiting pnorities and scientific agendas that meet these various needs. Support is
requested for Dr. Curiel (50%), Dr. Giles (5%), Dr. Naylor (10%), Dr. Ramirez (10%), Dr. Slaga (20%), and
Ms. McCarroll (50%). Some Senior Leadership also serve as Program Leaders, but generally those duties
are co-shared with Senior Leadership in terms of financial support. Thus, most support for the totality'of the
efforts of these individuals comes from Senior Leadership, freeing our scare resources in the budget for
additional, constructive uses in our Cancer Center.
高级领导者是具有必要技能的个人
对我们的癌症中心的完整视角,以确保其最佳增长,功能,资源利用和
内部和编程间相互作用。这些人也代表了癌症的相关方面
构成我们的矩阵环境的各种临床和研究实体的中心事务
癌症中心互动以获得最大优势,并且可以最好地利用可用的外部资源。
领导层包括癌症中心执行董事(Curiel博士)和副董事(Giles博士),我们的
三位科学副总监Slaga博士(基础和翻译研究),Naylor博士(共享
资源和内部教育)和Pollock博士(癌症预防和控制)。拉米雷斯博士担任
由于她在健康促进研究所的董事职位,高级领导
关键的预防癌症预防和西班牙裔外展功能。我们也有一个临时
行政管理副主任具有极大的增强权力,并明确担任高级领导职务
在先前的审查中要求。国家寻找常任行政管理主任的国家是
不道理的,期望在现场访问时填补永久职位。这
高级领导确保我们的癌症中心通过适当的
NCI,NIH及相关,机构和慈善资金的管理,将发现转化为
可满足南安东尼奥的临床和研究癌症护理需求的实际应用
德克萨斯州和国家。所有高级领导成员都坐在执行委员会和其他重要的
设定当前癌症中心议程的委员会,未来增长计划,挑战和机遇
并有助于制定预算,招募满足这些需求的专业和科学议程。支持是
要求库里尔博士(50%),吉尔斯博士(5%),奈勒博士(10%),拉米雷斯博士(10%),斯拉加博士(20%)和
麦卡罗尔女士(50%)。一些高级领导还担任计划领导者,但通常是这些职责
在财政支持方面与高级领导共同共享。因此,最大程度地支持
这些人的努力来自高级领导,释放了我们在预算中的恐慌资源
我们的癌症中心的其他建设性用途。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tyler J. Curiel其他文献
ESTABLISHMENT OF A DOUBLE-HUMANIZED MOUSE MODEL USING PATIENT-DERIVED XENOGRAFT BLADDER CANCER TUMOR CELL LINE AND HUMAN γδ T-CELLS
- DOI:
10.1016/j.urolonc.2024.01.171 - 发表时间:
2024-03-01 - 期刊:
- 影响因子:
- 作者:
Shaun Trecarten;Robert S. Svatek;Niannian Ji;Zhen-Ju Shu;Tyler J. Curiel;Neelam Mukherjee;Jamie Furman - 通讯作者:
Jamie Furman
PD48-06 2 YEAR CLINICAL AND IMMUNOLOGIC OUTCOMES OF INTRADERMAL BCG PRIMING PRIOR TO INTRAVESICAL INDUCTION IMMUNOTHERAPY FOR HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER
- DOI:
10.1016/j.juro.2017.02.2354 - 发表时间:
2017-04-01 - 期刊:
- 影响因子:
- 作者:
Niannan Ji;Edwin E. Morales;Neelam Mukherjee;Vincent Hurez;Tyler J. Curiel;Getahun Abate;Daniel F. Hoft;Robert S. Svatek - 通讯作者:
Robert S. Svatek
60: Oral rapamycin prevents carcinogen-induced dermal carcinogenesis through immune mechanisms
- DOI:
10.1016/j.cyto.2013.06.063 - 发表时间:
2013-09-01 - 期刊:
- 影响因子:
- 作者:
Vinh Dao;Vincent Hurez;Sri Lakshmi Pandeswara;Lishi Sun;Aijie Liu;Paul Hasty;Dave Sharp;Tyler J. Curiel - 通讯作者:
Tyler J. Curiel
Tyler J. Curiel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tyler J. Curiel', 18)}}的其他基金
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments
膀胱癌 PD-L1 对同源重组的控制:应用于新疗法的基本机制
- 批准号:
10467877 - 财政年份:2022
- 资助金额:
$ 7.5万 - 项目类别:
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments
膀胱癌 PD-L1 对同源重组的控制:应用于新疗法的基本机制
- 批准号:
10688261 - 财政年份:2022
- 资助金额:
$ 7.5万 - 项目类别:
Regulation of ER-beta Signaling in Carcinogenesis
ER-β 信号传导在癌发生过程中的调节
- 批准号:
10092967 - 财政年份:2019
- 资助金额:
$ 7.5万 - 项目类别:
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
(PQ2) 接受癌症免疫治疗的老年宿主体内的 PD-L1/PD-1 信号
- 批准号:
9788318 - 财政年份:2018
- 资助金额:
$ 7.5万 - 项目类别:
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
(PQ2) 接受癌症免疫治疗的老年宿主体内的 PD-L1/PD-1 信号
- 批准号:
10381324 - 财政年份:2018
- 资助金额:
$ 7.5万 - 项目类别:
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
(PQ2) 接受癌症免疫治疗的老年宿主体内的 PD-L1/PD-1 信号
- 批准号:
10475260 - 财政年份:2018
- 资助金额:
$ 7.5万 - 项目类别:
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
(PQ2) 接受癌症免疫治疗的老年宿主体内的 PD-L1/PD-1 信号
- 批准号:
10247570 - 财政年份:2018
- 资助金额:
$ 7.5万 - 项目类别:
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
(PQ
- 批准号:
9926828 - 财政年份:2017
- 资助金额:
$ 7.5万 - 项目类别:
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
(PQ
- 批准号:
9307468 - 财政年份:2017
- 资助金额:
$ 7.5万 - 项目类别:
Immune aspects of mTOR inhibition for cancer prevention (PQ5)
mTOR 抑制的免疫方面预防癌症 (PQ5)
- 批准号:
8538910 - 财政年份:2012
- 资助金额:
$ 7.5万 - 项目类别:
相似国自然基金
基于跨尺度自纠偏数字心脏的恶性基因突变智能预算方法研究
- 批准号:62306293
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
“预算-绩效”一体化背景下互动式目标生产对财政绩效的激励机制
- 批准号:72304179
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
我国地方政府预算稳定调节基金的政策效应和运行机制研究
- 批准号:72304284
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
地方债制度改革与企业劳动力投入:基于新《预算法》的准自然实验
- 批准号:72272166
- 批准年份:2022
- 资助金额:45 万元
- 项目类别:面上项目
合法性获取与国有企业预算目标设定:基于社会学视角的分析
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
University of Florida Health Cancer Center Support Grant
佛罗里达大学健康癌症中心支持补助金
- 批准号:
10625750 - 财政年份:2023
- 资助金额:
$ 7.5万 - 项目类别: